Glatiramer acetate in the treatment of multiple sclerosis: Emerging concepts regarding its mechanism of action

CNS Drugs

Volumn 25, Issue 5, 2011, Pages 401-414

  Lalive, Patrice H ^a,b   Neuhaus, Oliver ^c   Benkhoucha, Mahdia ^b   Burger, Danielle ^d   Hohlfeld, Reinhard ^e   Zamvil, Scott S ^f   Weber, Martin S ^g  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c Kliniken Landkreis Sigmaringen GmbH   (Germany)

^d UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^e UNIVERSITY OF MUNICH   (Germany)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Glatiramer acetate, pharmacodynamics; Immunomodulators, pharmacodynamics; Multiple sclerosis

Indexed keywords

GLATIRAMER; TRANSCRIPTION FACTOR FOXP3;

ADAPTIVE IMMUNITY; ALLERGIC ENCEPHALOMYELITIS; ALZHEIMER DISEASE; ANTIBODY PRODUCTION; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL POPULATION; CYTOKINE RELEASE; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; MONOCYTE; MULTIPLE SCLEROSIS; NERVE REGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PLASMA CELL; PRIORITY JOURNAL; REVIEW;

ANIMALS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MICE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROPROTECTIVE AGENTS; PEPTIDES;

EID: 79953890862     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11588120-000000000-00000     Document Type: Review

References (99)

1. Teitelbaum D, Meshorer A, Hirshfeld T, et al. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1971 Aug; 1 (4): 242-8
2. Teitelbaum D, Webb C, Bree M, et al. Suppression of ex-perimental allergic encephalomyelitis in Rhesus monkeys by a synthetic basic copolymer. Clin Immunol Immunopathol 1974 Nov; 3 (2): 256-62
3. Lisak RP, Zweiman B, Blanchard N, et al. Effect of treat-ment with Copolymer 1 (Cop-1) on the in vivo and in vitro manifestations of experimental allergic encephalomyelitis (EAE). J Neurol Sci 1983 Dec; 62 (1-3): 281-93 (Pubitemid 14176255)
4. Teitelbaum D, Fridkis-Hareli M, Arnon R, et al. Copolymer 1 inhibits chronic relapsing experimental allergic en-cephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. J Neuroimmunol 1996 Feb; 64 (2): 209-17 (Pubitemid 26094636)
5. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multi-center, double-blind, placebo-controlled trial. Neurology 1995; 45: 1268-76
6. Mikol DD, Barkhof F, Chang P, et al. Comparison of sub-cutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008 Oct; 7 (10): 903-14
7. O'Connor P, Filippi M, Arnason B, et al. 250 mug or 500 mug interferon beta-1b versus 20mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 2009 Oct; 8 (10): 889-97
8. Duda PW, Schmied MC, Cook SL, et al. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 2000; 105 (7): 967-76 (Pubitemid 30203069)
9. Neuhaus O, Farina C, Yassouridis A, et al. Multiple sclerosis: comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Natl Acad Sci USA 2000; 97 (13): 7452-7 (Pubitemid 30431484)
10. Vieira PL, Heystek HC, Wormmeester J, et al. Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. J Immunol 2003 May 1; 170 (9): 4483-8 (Pubitemid 36519953)
11. Hong J, Li N, Zhang X, et al. Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci USA 2005 May 3; 102 (18): 6449-54 (Pubitemid 40617463)
12. Weber MS, Prod'homme T, Youssef S, et al. Type II mono-cytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med 2007 Aug; 13 (8): 935-43 (Pubitemid 47222047)
13. Karandikar NJ, Crawford MP, Yan X, et al. Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis. J Clin Invest 2002 Mar; 109 (5): 641-9 (Pubitemid 34204843)
14. Weber MS, Starck M, Wagenpfeil S, et al. Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain 2004 Jun; 127 (Pt 6): 1370-8 (Pubitemid 38745515)
15. Kim HJ, Ifergan I, Antel JP, et al. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol 2004 Jun 1; 172 (11): 7144-53 (Pubitemid 38669158)
16. Stasiolek M, Bayas A, Kruse N, et al. Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis. Brain 2006 May; 129 (Pt 5): 1293-305
17. Stuve O, Youssef S, Weber MS, et al. Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest 2006 Apr; 116 (4): 1037-44
18. Burger D, Molnarfi N, Weber MS, et al. Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis. Proc Natl Acad Sci USA 2009 Mar 17; 106 (11): 4355-9
19. Kala M, Rhodes SN, Piao WH, et al. B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis. Exp Neurol 2010 Jan; 221 (1): 136-45
20. Begum-Haque S, Sharma A, Christy M, et al. Increased expression of B cell-associated regulatory cytokines by glatiramer acetate in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol 2010 Feb 26; 219 (1-2): 47-53
21. Aharoni R, Eilam R, Domev H, et al. The immunomod-ulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc Natl Acad Sci USA 2005 Dec 27; 102 (52): 19045-50 (Pubitemid 43049563)
22. Chen M, Valenzuela RM, Dhib-Jalbut S. Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor. J Neurol Sci 2003 Nov 15; 215 (1-2): 37-44 (Pubitemid 37279143)
23. Kipnis J, Yoles E, Porat Z, et al. T cell immunity to copoly-mer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc Natl Acad Sci USA 2000 Jun 20; 97 (13): 7446-51 (Pubitemid 30431483)
24. Ziemssen T, Kumpfel T, Klinkert WE, et al. Glatiramer acetate-specific T-helper 1-and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy -brain-derived neurotrophic factor. Brain 2002 Nov; 125 (Pt 11): 2381-91 (Pubitemid 35303499)
25. Skihar V, Silva C, Chojnacki A, et al. Promoting oligoden-drogenesis and myelin repair using the multiple sclerosis medication glatiramer acetate. Proc Natl Acad Sci USA 2009 Oct 20; 106 (42): 17992-7
26. Aharoni R, Herschkovitz A, Eilam R, et al. Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2008 Aug 12; 105 (32): 11358-63
27. Neuhaus O, Farina C, Wekerle H, et al. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 2001; 56 (6): 702-8 (Pubitemid 32240087)
28. Farina C, Weber MS, Meinl E, et al. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol 2005 Sep; 4 (9): 567-75 (Pubitemid 41139978)
29. Fridkis-Hareli M, Strominger JL. Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules. J Immunol 1998 May 1; 160 (9): 4386-97 (Pubitemid 28217296)
30. Fridkis-Hareli M, Teitelbaum D, Gurevich E, et al. Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells: specificity and promiscuity. Proc Natl Acad Sci USA 1994 May 24; 91 (11): 4872-6
31. Teitelbaum D, Milo R, Arnon R, et al. Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein. Proc Natl Acad Sci USA 1992 Jan 1; 89 (1): 137-41
32. Webb C, Teitelbaum D, Herz A, et al. Molecular require-ments involved in suppression of EAE by synthetic basic copolymers of amino acids. Immunochemistry 1976 Apr; 13 (4): 333-7
33. Aharoni R, Schlegel PG, Teitelbaum D, et al. Studies on the mechanism and specificity of the effect of the synthetic random copolymer GLAT on graft-versus-host disease. Immunol Lett 1997 Jul; 58 (2): 79-87 (Pubitemid 27348910)
34. Wiesemann E, Klatt J, Sonmez D, et al. Glatiramer acetate (GA) induces IL-13/IL-5 secretion in naive T cells. J Neuroimmunol 2001 Sep 3; 119 (1): 137-44 (Pubitemid 32781739)
35. Dhib-Jalbut S. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology 2002 Apr 23; 58 (8 Suppl. 4): S3-9 (Pubitemid 34411848)
36. Aharoni R, Teitelbaum D, Sela M, et al. Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune en-cephalomyelitis. Proc Natl Acad Sci USA 1997; 94 (20): 10821-6 (Pubitemid 27430819)
37. Aharoni R, Teitelbaum D, Leitner O, et al. Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. Proc Natl Acad Sci USA 2000; 97 (21): 11472-7
38. Chen M, Gran B, Costello K, et al. Glatiramer acetate in-duces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS. Mult Scler 2001 Aug; 7 (4): 209-19 (Pubitemid 32780690)
39. Aharoni R, Teitelbaum D, Sela M, et al. Bystander sup-pression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1. J Neuroimmunol 1998; 91 (1-2): 135-46 (Pubitemid 28545254)
40. Kantengwa S, Weber MS, Juillard C, et al. Inhibition of naive Th1 CD4+ T cells by glatiramer acetate in multiple sclerosis. J Neuroimmunol 2007 Apr; 185 (1-2): 123-9 (Pubitemid 46497430)
41. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003 Feb 14; 299 (5609): 1057-61 (Pubitemid 36222930)
42. Brunkow ME, Jeffery EW, Hjerrild KA, et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001 Jan; 27 (1): 68-73 (Pubitemid 32044521)
43. Kukreja A, Cost G, Marker J, et al. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 2002 Jan; 109 (1): 131-40 (Pubitemid 34052549)
44. Viglietta V, Baecher-Allan C, Weiner HL, et al. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004 Apr 5; 199 (7): 971-9 (Pubitemid 38481088)
45. Farina C, Then Bergh F, Albrecht H, et al. Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells. Brain 2001 Apr; 124 (Pt 4): 705-19 (Pubitemid 32303830)
46. Tennakoon DK, Mehta RS, Ortega SB, et al. Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis. J Immunol 2006 Jun 1; 176 (11): 7119-29 (Pubitemid 43787894)
47. Biegler BW, Yan SX, Ortega SB, et al. Glatiramer acetate (GA) therapy induces a focused, oligoclonal CD8+ T-cell repertoire in multiple sclerosis. J Neuroimmunol 2006 Nov; 180 (1-2): 159-71 (Pubitemid 44692328)
48. Teitelbaum D, Brenner T, Abramsky O, et al. Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy. Mult Scler 2003 Dec; 9 (6): 592-9 (Pubitemid 37479408)
49. Farina C, Vargas V, Heydari N, et al. Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients. J Neuroimmunol 2002 Feb; 123 (1-2): 188-92 (Pubitemid 34195620)
50. Kappos L, Clanet M, Sandberg-Wollheim M, et al. Neu-tralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 2005 Jul 12; 65 (1): 40-7 (Pubitemid 40967774)
51. Karussis D, Teitelbaum D, Sicsic C, et al. Long-term treat-ment of multiple sclerosis with glatiramer acetate: natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy. J Neuroimmunol 2010 Mar 30; 220 (1-2): 125-30
52. Brenner T, Arnon R, Sela M, et al. Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone. J Neuroimmunol 2001 Apr 2; 115 (1-2): 152-60 (Pubitemid 32245663)
53. Ure DR, Rodriguez M. Polyreactive antibodies to glatir-amer acetate promote myelin repair in murine model of demyelinating disease. FASEB J 2002 Aug; 16 (10): 1260-2
54. Weber MS, Prod'homme T, Patarroyo JC, et al. B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system au-toimmunity. Ann Neurol 2010 Sep; 68 (3): 369-83
55. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008 Feb 14; 358 (7): 676-88 (Pubitemid 351240747)
56. Bar-Or A, Fawaz L, Fan B, et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol 2010 Apr; 67 (4): 452-61
57. Fillatreau S, Sweenie CH, McGeachy MJ, et al. B cells reg-ulate autoimmunity by provision of IL-10. Nat Immunol 2002 Oct; 3 (10): 944-50 (Pubitemid 35154008)
58. Mann MK, Maresz K, Shriver LP, et al. B cell regulation of CD4 +CD25+ T regulatory cells and IL-10 via B7 is essential for recovery from experimental autoimmune en-cephalomyelitis. J Immunol 2007 Mar 15; 178 (6): 3447-56 (Pubitemid 46417609)
59. Bouaziz JD, Yanaba K, Tedder TF. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev 2008 Aug; 224: 201-14
60. De Smedt T, Van Mechelen M, De Becker G, et al. Effect of interleukin-10 on dendritic cell maturation and function. Eur J Immunol 1997 May; 27 (5): 1229-35 (Pubitemid 27197228)
61. Li Q, Milo R, Panitch H, et al. Glatiramer acetate blocks the activation of THP-1 cells by interferon-gamma. Eur J Pharmacol 1998 Jan 26; 342 (2-3): 303-10 (Pubitemid 28149984)
62. Hussien Y, Sanna A, Soderstrom M, et al. Glatiramer acet-ate and IFN-beta act on dendritic cells in multiple sclerosis. J Neuroimmunol 2001 Dec 3; 121 (1-2): 102-10 (Pubitemid 34008457)
63. Jung S, Siglienti I, Grauer O, et al. Induction of IL-10 in rat peritoneal macrophages and dendritic cells by glatiramer acetate. J Neuroimmunol 2004 Mar; 148 (1-2): 63-73 (Pubitemid 38229559)
64. Sanna A, Fois ML, Arru G, et al. Glatiramer acetate reduces lymphocyte proliferation and enhances IL-5 and IL-13 production through modulation of monocyte-derived dendritic cells in multiple sclerosis. Clin Exp Immunol 2006 Feb; 143 (2): 357-62
65. Carpintero R, Brandt KJ, Gruaz L, et al. Glatiramer acetate triggers PI3Kdelta/Akt and MEK/ERK pathways to induce IL-1 receptor antagonist in human monocytes. Proc Natl Acad Sci USA 2010 Oct 12; 107 (41): 17692-7
66. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006 May 11; 441 (7090): 235-8
67. Korn T, Mitsdoerffer M, Croxford AL, et al. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc Natl Acad Sci USA 2008 Nov 25; 105 (47): 18460-5
68. Korn T, Oukka M, Kuchroo V, et al. Th17 cells: effector T cells with inflammatory properties. Semin Immunol 2007 Dec; 19 (6): 362-71 (Pubitemid 351274046)
69. Mombaerts P, Iacomini J, Johnson RS, et al. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 1992 Mar 6; 68 (5): 869-77
70. Aharoni R, Kayhan B, Eilam R, et al. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc Natl Acad Sci USA 2003 Nov 25; 100 (24): 14157-62 (Pubitemid 37499207)
71. Allie R, Hu L, Mullen KM, et al. Bystander modulation of chemokine receptor expression on peripheral blood T lymphocytes mediated by glatiramer therapy. Arch Neurol 2005 Jun; 62 (6): 889-94 (Pubitemid 40973450)
72. Zhang M, Chan CC, Vistica B, et al. Copolymer 1 inhibits experimental autoimmune uveoretinitis. J Neuroimmunol 2000 Mar 1; 103 (2): 189-94 (Pubitemid 30079731)
73. Gur C, Karussis D, Golden E, et al. Amelioration of ex-perimental colitis by Copaxone is associated with class-II-restricted CD4 immune blocking. Clin Immunol 2006 Feb-Mar; 118 (2-3): 307-16 (Pubitemid 43199670)
74. Arnon R, Aharoni R. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci USA 2004 Oct 5; 101 Suppl. 2: 14593-8 (Pubitemid 39346729)
75. Kerschensteiner M, Stadelmann C, Dechant G, et al. Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Ann Neurol 2003 Mar; 53 (3): 292-304 (Pubitemid 36258633)
76. Riley CP, Cope TC, Buck CR. CNS neurotrophins are bio-logically active and expressed by multiple cell types. J Mol Histol 2004 Nov; 35 (8-9): 771-83 (Pubitemid 41404623)
77. Kerschensteiner M, Gallmeier E, Behrens L, et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med 1999 Mar 1; 189 (5): 865-70 (Pubitemid 29189691)
78. Stadelmann C, Kerschensteiner M, Misgeld T, et al. BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain 2002 Jan; 125 (Pt 1): 75-85 (Pubitemid 34084038)
79. Maier K, Kuhnert AV, Taheri N, et al. Effects of glatiramer acetate and interferon-beta on neurodegeneration in a model of multiple sclerosis: a comparative study. Am J Pathol 2006 Oct; 169 (4): 1353-64 (Pubitemid 351194369)
80. Aharoni R, Arnon R, Eilam R. Neurogenesis and neuro-protection induced by peripheral immunomodulatory treatment of experimental autoimmune encephalomyelitis. J Neurosci 2005 Sep 7; 25 (36): 8217-28 (Pubitemid 41292116)
81. Gilgun-Sherki Y, Panet H, Holdengreber V, et al. Axonal damage is reduced following glatiramer acetate treatment in C57/bl mice with chronic-induced experimental autoimmune encephalomyelitis. Neurosci Res 2003 Oct; 47 (2): 201-7 (Pubitemid 37152456)
82. Liu J, Johnson TV, Lin J, et al. T cell independent mechan-ism for copolymer-1-induced neuroprotection. Eur J Immunol 2007 Nov; 37 (11): 3143-54 (Pubitemid 350131293)
83. Azoulay D, Vachapova V, Shihman B, et al. Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate. J Neuroimmunol 2005 Oct; 167 (1-2): 215-8 (Pubitemid 41242305)
84. Filippi M, Rovaris M, Rocca MA, et al. Glatiramer acetate reduces the proportion of new MS lesions evolving into 'black holes'. Neurology 2001 Aug 28; 57 (4): 731-3 (Pubitemid 32783013)
85. Khan O, Shen Y, Bao F, et al. Long-term study of brain 1H-MRS study in multiple sclerosis: effect of glatiramer acetate therapy on axonal metabolic function and feasibility of long-Term H-MRS monitoring in multiple sclerosis. J Neuroimaging 2008 Jul; 18 (3): 314-9
86. Franklin RJ. Why does remyelination fail in multiple sclerosis? Nat Rev Neurosci 2002 Sep; 3 (9): 705-14 (Pubitemid 135706676)
87. Lalive PH, Paglinawan R, Biollaz G, et al. TGF-betatreated microglia induce oligodendrocyte precursor cell chemo-taxis through the HGF-c-Met pathway. Eur J Immunol 2005 Mar; 35 (3): 727-37 (Pubitemid 40425528)
88. Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med 2000; 343 (13): 938-52
89. Wolinsky JS. The diagnosis of primary progressive multiple sclerosis. J Neurol Sci 2003 Feb 15; 206 (2): 145-52 (Pubitemid 36143719)
90. Wolinsky JS, Narayana PA, O'Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007 Jan; 61 (1): 14-24 (Pubitemid 46214240)
91. Butovsky O, Koronyo-Hamaoui M, Kunis G, et al. Glatir-amer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Proc Natl Acad Sci USA 2006 Aug 1; 103 (31): 11784-9 (Pubitemid 44182528)
92. Frenkel D, Maron R, Burt DS, et al. Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. J Clin Invest 2005 Sep; 115 (9): 2423-33 (Pubitemid 41266204)
93. Benner EJ, Mosley RL, Destache CJ, et al. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA 2004 Jun 22; 101 (25): 9435-40 (Pubitemid 38812892)
94. Angelov DN, Waibel S, Guntinas-Lichius O, et al. Ther-apeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2003 Apr 15; 100 (8): 4790-5 (Pubitemid 36457807)
95. Aharoni R, Kayhan B, Arnon R. Therapeutic effect of the immunomodulator glatiramer acetate on trinitrobenzene sulfonic acid-induced experimental colitis. Inflamm Bowel Dis 2005 Feb; 11 (2): 106-15 (Pubitemid 40711214)
96. Aharoni R, Sonego H, Brenner O, et al. The therapeutic effect of glatiramer acetate in a murine model of inflammatory bowel disease is mediated by anti-inflammatory T-cells. Immunol Lett 2007 Oct 15; 112 (2): 110-9 (Pubitemid 47379855)
97. Neesse A, Michl P, Kunsch S, et al. Glatiramer acetate: a novel therapeutic approach in Crohn's disease? Inflamm Bowel Dis 2009 Jan; 15 (1): 156-7
98. Zheng B, Switzer K, Marinova E, et al. Exacerbation of autoimmune arthritis by copolymer-I through promoting type 1 immune response and autoantibody production. Autoimmunity 2008 Aug; 41 (5): 363-71 (Pubitemid 351891197)
99. Borel P, Benkhoucha M, Weber MS, et al. Glatiramer acetate treatment does not modify the clinical course of (NZB x BXSB)F1 lupus murine model. Int Immunol 2008 Oct; 20 (10): 1313-9